Effect of 5-aminolevulinic Acid on Mitochondrial Activity

Yuliya V Markina1, Alexander M Markin1,2, Tatiana V Kirichenko1

  • 1Laboratory of Cellular and Molecular Pathology of Cardiovascular System, Avtsyn Research Institute of Human Morphology of FSBSI "Petrovsky National Research Centre of Surgery", 119991 Moscow, Russia.

Abstract

Insights

Phototherapy using 5-aminolevulinic acid (ALA) shows promise for treating diseases linked to mitochondrial dysfunction. This study found varying mitochondrial potential decreases across cell lines with different mutation loads, suggesting personalized therapeutic strategies.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Genetics

Background:

  • Mitochondrial dysfunction is a key factor in numerous diseases.
  • Mitochondria are targets for novel therapies, including 5-aminolevulinic acid (ALA) phototherapy.
  • Investigating mitochondrial activity in cells with varying mutation loads is crucial for understanding disease mechanisms.

Purpose of the Study:

  • To assess mitochondrial activity in cells with diverse mitochondrial mutation burdens.
  • To evaluate the impact of 5-aminolevulinic acid (ALA) on mitochondrial function in these cells.
  • To explore the potential for personalized phototherapy based on mitochondrial health.

Main Methods:

  • Utilized 11 cybrid cell lines derived from the THP-1 cell line.
  • Examined platelets from patients harboring distinct mitochondrial mutations.
  • Analyzed cellular response to 5-aminolevulinic acid (ALA) treatment.

Main Results:

  • 5-aminolevulinic acid (ALA) was equally metabolized across all tested cell lines.
  • A significant reduction in mitochondrial membrane potential was observed.
  • The extent of mitochondrial potential decrease varied notably among the different cell lines.

Conclusions:

  • Cellular response to ALA phototherapy is influenced by mitochondrial mutation load.
  • Observed differences in mitochondrial potential suggest a basis for personalized treatment strategies.
  • This research supports the development of tailored therapeutic approaches for mitochondrial diseases.